Credit Suisse’s Acumen Pharmaceuticals ABOS Stock Holding History

Credit Suisse’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-15	Closed	–	–	4010
2022 Q2	$0	Buy	+15	New	+$56	﹤0.01%	3874

Other funds holding ABOS

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Pathstone Family Office Englewood, New Jersey $13.1B AUM 21.02% 1-Year Est. Return

Credit Suisse's ABOS Position: Q3 2022 in Review

Credit Suisse sold out of Acumen Pharmaceuticals (ABOS) in Q3 2022, closing a stake of 15 shares.

Credit Suisse first reported a position in ABOS in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 50 funds tracked by Wall St. Rank hold ABOS as of Q3 2022.

Credit Suisse reported no remaining Acumen Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Credit Suisse sold 15 Acumen Pharmaceuticals shares in Q3 2022.
Credit Suisse first reported a position in Acumen Pharmaceuticals in Q2 2022 and held it in 1 quarter.
Credit Suisse's Acumen Pharmaceuticals position peaked at $0 in Q2 2022.
50 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.